MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review.

This article, published in the March 2012 issue of EMBO Molecular Medicine, contained text passages similar to those from a number of previous publications, many by the same authors: “Cancer microRNAs: from subtype profiling to predictors of response to therapy” by Chan E, Pardo DE, Weidhaas JB in Trends Mol Med 17: 235–243; “Targeting microRNAs in cancer: rationale, strategies and challenges” by Garson R, Marcucci G, Croce CM in Nat Rev Drug Discov 9: 775–789; “MicroRNAs in cancer: small molecules with a huge impact” by Iorio MV, Croce CM in J Clin Oncol 27: 5848–5856; and “Breast cancer and microRNAs: therapeutic impact” by Iorio MV, Casalini P, Piovan C, Braccioli L, Tagliabue E in Breast 20 Suppl. 3: S63–S70. Formal citations to the original articles were inadvertently omitted.

Similarly, a number of later publications overlap with text from this reference without formal citations. These are as follows: “microRNA: new players in metastatic process” by Triulzi T, Iorio MV, Tagliabue E, Casalini P in Oncogene and cancer—from bench to clinic, Siregar Y (ed.), Chapter 16. Rijeka: InTech; “microRNA involvement in human cancer” by Iorio MV, Croce CM in Carcinogenesis 33: 1126–1133; and “Causes and consequences of microRNA dysregulation” by Iorio MV, Croce CM in Cancer J, 18: 215–222. The authors apologize for this oversight.